US FDA reviewers: Janssen's MDR-TB drug bedaquiline safe, effective
This article was originally published in Scrip
Janssen's experimental oral medicine bedaquiline 100mg is more effective than placebo in treating multi-drug resistance in Mycobacterium tuberculosis (MDR-TB) based on a surrogate endpoint of sputum culture conversion (SCC), with trial data showing the drug is safe and well-tolerated, although US FDA drug reviewers raised some concern about an increase in QTcF with the 400mg dosage.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.